TransCode Therapeutics, Inc. Appoints Jack Stover to Board of Directors

TransCode Therapeutics, Inc. announced the appointment of Jack Stover to its Board of Directors, effective December 19, 2025. Mr. Stover, deemed an independent director and financial expert, brings extensive executive leadership experience from the life sciences industry, including roles at Traws Pharma, Inc., Onconova Therapeutics, Inc., NorthView Acquisition Corp., Profusa, Inc., Stero Therapeutics, Inc., PharmaCyte Biotech, Inc., Interpace Biosciences, Inc., Antares Pharma Inc., and PricewaterhouseCoopers. He will serve on the Audit Committee and the Nominating and Corporate Governance Committee. This appointment follows the resignation of Dr. Magda Marquet from the Audit Committee. Mr. Stover will receive standard compensation for non-employee directors. The company also issued a press release on December 22, 2025, announcing this appointment.